State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia

被引:0
|
作者
Susan F. Sonnenschein
Kathryn M. Gill
Anthony A. Grace
机构
[1] University of Pittsburgh,Departments of Neuroscience, Psychiatry and Psychology, Center for Neuroscience
来源
Neuropsychopharmacology | 2019年 / 44卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Aripiprazole is an antipsychotic drug characterized by partial agonist activity at D2 receptors to normalize both hyperdopaminergic and hypodopaminergic states. Traditional D2 antagonist antipsychotic drugs have been shown previously to reduce dopamine neuron activity through action on D2 autoreceptors to produce an overexcitation-induced cessation of cell firing, referred to as depolarization block. It is unclear whether aripiprazole reduces dopamine neuron activity via inhibition or, as seen following D2 antagonist administration, depolarization block. The impact of acute and repeated aripiprazole treatment was examined in the methylazoxymethanol acetate (MAM) rodent model to observe its effects on a hyperdopaminergic system, compared to normal rats. We found that administration of aripiprazole acutely or after 1 or 7 days of withdrawal from 21-day repeated treatment led to a decrease in the number of spontaneously active dopamine neurons in MAM rats but not in controls. This reduction was not reversed by apomorphine (100–200 µg/kg i.p. or 20 µg/kg i.v.) administration, suggesting that it was not due to depolarization block. In contrast, 1 h after induction of depolarization block of dopamine neurons by acute haloperidol treatment (0.6 mg/kg i.p.), aripiprazole (1 mg/kg, i.p.) reversed the depolarization block state. Therefore, aripiprazole rapidly reduced the hyperdopaminergic activity selectively in MAM rats. The reduction is unlikely due to depolarization block and persists following 7-day withdrawal from repeated treatment. Aripiprazole also removes haloperidol-induced depolarization block in MAM rats, which may underlie the acute psychotic state often observed with switching to this treatment.
引用
收藏
页码:572 / 580
页数:8
相关论文
共 50 条
  • [1] STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA
    Sonnenschein, Susan
    Gill, Kathryn
    Grace, Anthony
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S338 - S338
  • [2] State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia
    Sonnenschein, Susan F.
    Gill, Kathryn M.
    Grace, Anthony A.
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (03) : 572 - 580
  • [3] Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic
    Keck, PE
    McElroy, SL
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (04) : 655 - 662
  • [4] Aripiprazole acts as a selective dopamine D2 receptor partial agonist
    Wood, Martyn
    Reavill, Charlie
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (06) : 771 - 775
  • [5] The Synthesis of a Dopamine D2 Partial Agonist for the Treatment of Schizophrenia
    Magano, Javier
    Acciacca, Alison
    Akin, Anne
    Collman, Benjamin M.
    Conway, Brian
    Waldo, Michael
    Chen, Michael H.
    Mennen, Kenneth E.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2009, 13 (03) : 555 - 566
  • [6] Pharmacology of aripiprazole, a novel antipsychotic:: dopamine D2 receptor partial agonist
    Kikuchi, T
    Arlene, S
    Yocca, F
    Tadori, Y
    Hirose, T
    McQuade, R
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 190 - 190
  • [7] Aripiprazole, a novel antipsychotic, is a potent partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Ryan, E
    Xu, C
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 88 - 88
  • [8] The dopamine D3-preferring D2/D3 dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia
    Watson, David J. G.
    King, Madeleine V.
    Gyertyan, Istvan
    Kiss, Bela
    Adham, Nika
    Fone, Kevin C. F.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 (02) : 208 - 224
  • [9] A NOVEL α5GABAAR AGONIST REVERSES HIPPOCAMPAL OVERDRIVE OF DOPAMINE NEURON ACTIVITY IN THE MAM MODEL OF SCHIZOPHRENIA
    Gill, Kathryn M.
    Lodge, Daniel J.
    Grace, Anthony A.
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 246 - 246
  • [10] THE DOPAMINE D2 RECEPTOR PARTIAL AGONIST ARIPIPRAZOLE REDUCES ESCALATED ALCOHOL SELF-ADMINISTRATION IN DEPENDENT MICE
    Becker, H. C.
    Lopez, M. F.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2014, 38 : 306A - 306A